

Special Issue

Innovations in the Clinical Research of Chronic Myeloid Leukemia: From Targeted Therapies to Allogeneic Stem Cell Transplantation

Message from the Guest Editor

Chronic myeloid leukemia (CML) has undergone remarkable therapeutic advancements in recent decades, transforming it from a fatal disease to a manageable chronic condition for most patients. The introduction of tyrosine kinase inhibitors (TKIs) revolutionized CML treatment, yet challenges remain in managing resistance, treatment discontinuation, and disease progression. Allogeneic stem cell transplantation continues to play a crucial role for eligible patients, particularly those with advanced disease or TKI failure. This Special Issue aims to highlight the latest innovations in CML clinical research, spanning from novel targeted therapies to optimized transplantation approaches.

Guest Editor

Dr. Jeffrey H. Lipton

Hans Messner Allogeneic Blood and Marrow Transplant Program,
Princess Margaret Cancer Centre, Toronto, ON M5G 2C4, Canada

Deadline for manuscript submissions

28 February 2026



Current Oncology

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 4.9
Indexed in PubMed



mdpi.com/si/240086

Current Oncology
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
currentoncology@mdpi.com

[mdpi.com/journal/
currentoncology](https://mdpi.com/journal/currentoncology)





Current Oncology

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 4.9
Indexed in PubMed



[mdpi.com/journal/
currentcol](https://mdpi.com/journal/currentcol)



About the Journal

Message from the Editor-in-Chief

I am honored and enthusiastic to serve as Editor-in-Chief of *Current Oncology*. Since its establishment in 1994, *Current Oncology* has been playing an important role in the advancement of cancer care by disseminating new knowledge in the cancer care continuum. *Current Oncology* is affiliated with several key cancer societies and provides a global platform to share scientific progress in oncology. We strive for high standards and work together to maintain a rigorous and unbiased peer review process to publish high-quality articles. We have an outstanding editorial team which is committed to the success of *Current Oncology*.

Editor-in-Chief

Prof. Dr. Shahid Ahmed

1. College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada

2. Saskatchewan Cancer Agency, Saskatoon Cancer Center, Saskatoon, SK S7N5H5, Canada

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, and other databases.

Journal Rank:

JCR - Q2 (Oncology)